Dr. Hariharan.S

Dr. Hariharan.S |Clyto Access

Regional Cancer Centre, India.



Biography: Dr. Hariharan.S carried out his Ph. D in the Cancer Cytogenetic and Molecular Biology, Regional cancer center, Thiruvananthapuram, University of Kerala, India. Later he started working as Associate Professor and Head, Laboratory Of Cytogenetic and Molecular Diagnostics Division of Cancer Research, Regional Cancer Centre, India.,


Title: The Importance of Cytogenetic and Molecular studies in the Prognosis prediction of Acute Myeloid Leukemia Patients.

Abstract: Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. The overall 5- year survival rate for AML is still less than 50% in adults and significantly lower in the elderly. Accurate diagnosis and optimal use of prognostic markers along with expertise in management are the key elements for success. In approximately 50% of cases, specific recurrent chromosomal aberrations can be identified by modern cytogenetic techniques. This information is the single most important tool to classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate, and poor risk. Currently, favorable risk AML patients are usually treated with contemporary chemotherapy while poor risk AML patients receive allogeneic stem cell transplantation. The largest subgroup of AML patients (~50%) have no identifiable cytogenetic abnormalities and are classified as intermediate risk. The optimal therapeutic strategies for these patients are still largely unclear. Recently, it is becoming increasingly evident that it is possible to identify a subgroup of poorer risk patients among those with normal cytogenetic AML (NC-AML). Numerous molecular lesions found in AML patients serve as prognostic and predictive factors; some of these markers have been included in the latest WHO classification. The analysis of cryptic genomic changes and alterations of gene expression is particularly important in cytogenetically normal AML patients.  Molecular risk stratification for NC-AML patients may be possible due to mutations of NPM1, FLT3, CEBP and IDH. The current study mainly focusing on the cytogenetic and molecular abnormalities of AML patients in Kerala, India.,

Related Conferences :

International Conference on Cancer Care and Cure